| Year |
Citation |
Score |
| 2021 |
Almahmoud S, Elix CC, Jones JO, Hopkins CR, Vennerstrom JL, Zhong HA. Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents. Bioorganic & Medicinal Chemistry. 46: 116368. PMID 34433102 DOI: 10.1016/j.bmc.2021.116368 |
0.305 |
|
| 2020 |
Zengin ZB, Dizman N, Salgia N, Jones J, Zhang J, Liu Y, Xu B, Li F, Wang Y, Li M, Du R, Zhou Y, Hsu J, Salgia M, Yang L, et al. Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 38: e17100-e17100. DOI: 10.1200/Jco.2020.38.15_Suppl.E17100 |
0.307 |
|
| 2019 |
Elix CC, Salgia MM, Otto-Duessel M, Copeland BT, Yoo C, Lee M, Tew BY, Ann D, Pal SK, Jones JO. Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms. The Prostate. PMID 31769890 DOI: 10.1002/Pros.23928 |
0.42 |
|
| 2019 |
Copeland BT, Du J, Pal SK, Jones JO. Factors that influence the androgen receptor cistrome in benign and malignant prostate cells. Molecular Oncology. PMID 31520575 DOI: 10.1002/1878-0261.12572 |
0.442 |
|
| 2019 |
Salgia MM, Elix CC, Pal SK, Jones JO. Different roles of peroxisome proliferator-activated receptor gamma isoforms in prostate cancer. American Journal of Clinical and Experimental Urology. 7: 98-109. PMID 31317050 |
0.365 |
|
| 2019 |
Pal SK, Moreira D, Won H, White SW, Duttagupta P, Lucia M, Jones J, Hsu J, Kortylewski M. Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy. International Journal of Molecular Sciences. 20. PMID 31013891 DOI: 10.3390/Ijms20081831 |
0.366 |
|
| 2019 |
Pal SK, Tew BY, Lim M, Stankavich B, He M, Pufall M, Hu W, Chen Y, Jones JO. Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium. Acs Omega. 4: 2472-2481. PMID 30873507 DOI: 10.1021/acsomega.8b03205 |
0.319 |
|
| 2019 |
Copeland B, Du J, Yoo C, Jones J. OR34-3 The Androgen Receptor Malignancy Shift Can Be Caused by Mutations Commonly Found in Primary Prostate Cancer Journal of the Endocrine Society. 3. DOI: 10.1210/Js.2019-Or34-3 |
0.413 |
|
| 2019 |
Bergerot PG, Arvinitis L, Dizman N, Salgia M, Pal SK, Jones J. Assessment of the androgen receptor (AR) activity score versus AR expression in muscle invasive bladder cancer (MIBC). Journal of Clinical Oncology. 37: 463-463. DOI: 10.1200/Jco.2019.37.7_Suppl.463 |
0.36 |
|
| 2019 |
Adashek JJ, Won H, Moreira D, Duttagupta P, Twardowski P, Jones J, Kortylewski M, Pal SK. Effect of IL-6 and related mediators on resistance to abiraterone acetate (abi) and enzalutamide (enza) in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 296-296. DOI: 10.1200/Jco.2019.37.7_Suppl.296 |
0.303 |
|
| 2019 |
Lariviere MJ, Haas NB, Cherkas Y, Nielsen K, Foulk B, Patel J, Smirnov D, Vaughn DJ, Amaravadi RK, Savitch SL, Majmundar K, Buckingham TH, Yee SS, Jones J, Pal SK, et al. Prediction of metastatic castrate-resistant prostate cancer response to abiraterone or enzalutamide by a baseline blood-based CTC gene expression signature. Journal of Clinical Oncology. 37: e16529-e16529. DOI: 10.1200/Jco.2019.37.15_Suppl.E16529 |
0.403 |
|
| 2018 |
Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, et al. Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. The Oncologist. 23: 1413-e151. PMID 30575560 DOI: 10.1634/Theoncologist.2018-0652 |
0.353 |
|
| 2018 |
Copeland BT, Pal SK, Bolton EC, Jones JO. The androgen receptor malignancy shift in prostate cancer. The Prostate. PMID 29473182 DOI: 10.1002/Pros.23497 |
0.439 |
|
| 2018 |
Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK. The Role of Circulating Tumor DNA in Renal Cell Carcinoma. Current Treatment Options in Oncology. 19: 10. PMID 29464405 DOI: 10.1007/S11864-018-0530-4 |
0.351 |
|
| 2017 |
Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO. Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide. Urologic Oncology. PMID 29289429 DOI: 10.1016/J.Urolonc.2017.12.006 |
0.454 |
|
| 2017 |
Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). Cancer. PMID 29266182 DOI: 10.1002/Cncr.31161 |
0.383 |
|
| 2017 |
Bergerot P, Agarwal N, Pal SK, Jones JO. Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far From the Tree. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28912138 DOI: 10.1158/1078-0432.Ccr-17-2039 |
0.302 |
|
| 2017 |
Elix C, Pal SK, Jones JO. The role of peroxisome proliferator-activated receptor gamma in prostate cancer. Asian Journal of Andrology. PMID 28597850 DOI: 10.4103/Aja.Aja_15_17 |
0.462 |
|
| 2017 |
Won H, Moreira D, Gao C, Duttagupta P, Zhao X, Manuel E, Diamond D, Yuan YC, Liu Z, Jones J, D'Apuzzo M, Pal S, Kortylewski M. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. Journal of Leukocyte Biology. PMID 28533357 DOI: 10.1189/Jlb.3Ma1016-451Rr |
0.458 |
|
| 2017 |
Tew BY, Hong TB, Otto-Duessel M, Elix C, Castro E, He M, Wu X, Pal SK, Kalkum M, Jones JO. Vitamin K epoxide reductase regulation of androgen receptor activity. Oncotarget. PMID 28099154 DOI: 10.18632/Oncotarget.14639 |
0.427 |
|
| 2017 |
Salgia M, Perez ML, Jones J, Won HJ, Poroyko V, Twardowski P, Kortylewski M, Pal SK. Abstract LB-058: ABIraterone (ABI) and ENZalutamide (ENZ) induce changes in immunologic profile of patients with metastatic castration-resistant prostate cancer (mCRPC) Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-058 |
0.409 |
|
| 2017 |
Dizman N, Patel J, He M, Foulk B, Smirnov DA, Hsu J, Twardowski P, Kortylewski M, Bhargava V, Jones J, Pal SK. 1670PSerial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx390.042 |
0.429 |
|
| 2016 |
Zhou Y, Copeland B, Otto-Duessel M, He M, Markel S, Synold TW, Jones JO. Low Testosterone Alters the Activity of Mouse Prostate Stem Cells. The Prostate. PMID 27976414 DOI: 10.1002/Pros.23290 |
0.401 |
|
| 2016 |
Tew BY, Pal SK, He M, Tong T, Wu H, Hsu J, Liu X, Neuhausen SL, Jones JO. Vitamin K epoxide reductase expression and prostate cancer risk. Urologic Oncology. PMID 27889279 DOI: 10.1016/J.Urolonc.2016.10.020 |
0.408 |
|
| 2016 |
Vuong W, Tew BY, Little GH, Frenkel B, Jones JO. High-throughput screen for inhibitors of androgen receptor-RUNX2 transcriptional regulation in prostate cancer. The Journal of Pharmacology and Experimental Therapeutics. PMID 27554677 DOI: 10.1124/Jpet.116.234567 |
0.455 |
|
| 2016 |
Jones J, Tew BY, otto-Duessel M, Tong T, Kalkum M, Hong T, Liu X, Pal SK. Understanding the mechanism of warfarin-mediated PC prevention. Journal of Clinical Oncology. 34: e635-e635. DOI: 10.1200/Jco.2016.34.2_Suppl.E635 |
0.461 |
|
| 2016 |
Jones J, otto-Duessel M, Zhou Y, Pal SK. AR DNA binding domain inhibitors to treat AR splice variant-driven prostate cancer. Journal of Clinical Oncology. 34: 293-293. DOI: 10.1200/Jco.2016.34.2_Suppl.293 |
0.392 |
|
| 2015 |
Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, Agarwal N, Jones JO. Clinical and translational assessment of VEGFR1 as a mediator of the pre-metastatic niche in high-risk localized prostate cancer. Molecular Cancer Therapeutics. PMID 26450920 DOI: 10.1158/1535-7163.Mct-15-0367 |
0.328 |
|
| 2015 |
Liang M, Adisetiyo H, Liu X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ. Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. Plos One. 10: e0131232. PMID 26196517 DOI: 10.1371/Journal.Pone.0131232 |
0.458 |
|
| 2015 |
Moreira D, Zhang Q, Hossain DM, Nechaev S, Li H, Kowolik CM, D'Apuzzo M, Forman S, Jones J, Pal SK, Kortylewski M. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Oncotarget. PMID 26046794 DOI: 10.18632/Oncotarget.4029 |
0.466 |
|
| 2015 |
Pal SK, Agarwal N, Jones JO. Circulating tumor cells in prostate cancer: Does (nuclear) size matter? Cancer. PMID 25980931 DOI: 10.1002/Cncr.29454 |
0.418 |
|
| 2015 |
Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, Jones J, D'Apuzzo M, Forman S, Kortylewski M. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25967142 DOI: 10.1158/1078-0432.Ccr-14-3145 |
0.447 |
|
| 2015 |
Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, Agarwal N, Kawachi M, Yen Y, Jones JO. Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clinical Genitourinary Cancer. 13: 130-6. PMID 25450039 DOI: 10.1016/J.Clgc.2014.08.014 |
0.395 |
|
| 2015 |
Zhou Y, Bolton EC, Jones JO. Androgens and androgen receptor signaling in prostate tumorigenesis. Journal of Molecular Endocrinology. 54: R15-29. PMID 25351819 DOI: 10.1530/Jme-14-0203 |
0.436 |
|
| 2015 |
Pal SK, Hossain DM, Zhang Q, Frankel PH, Jones JO, Carmichael C, Ruel C, Lau C, Kortylewski M. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile. The Journal of Urology. 193: 1114-21. PMID 25286010 DOI: 10.1016/J.Juro.2014.09.110 |
0.302 |
|
| 2015 |
Pal SK, He M, Tong T, Wu H, Liu X, Lau C, Wang JH, Warden C, Wu X, Signoretti S, Choueiri TK, Karam JA, Jones JO. RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Molecular Cancer Research : McR. 13: 130-7. PMID 25183163 DOI: 10.1158/1541-7786.Mcr-14-0352 |
0.331 |
|
| 2015 |
He M, Tew BY, Cy S, Rideout D, Pal SK, Jones JO. Elucidation of the Multiple Activities of Abiraterone by a Synthetic Chemistry Approach Clinical and Experimental Pharmacology. 5: 1-4. DOI: 10.4172/2161-1459.1000173 |
0.323 |
|
| 2015 |
Zhou Y, Jones J. Abstract LB-126: Declining T levels provide increased opportunity for mutagenesis in prostate stem cells Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-126 |
0.367 |
|
| 2015 |
Yang L, Chen L, Wang Y, Jones J, Yen Y, Loera S, Pillai R, Chu P, Weisenburger D. Abstract 4880: Characterization of genetic concordance between primary tumor cells, circulating tumor cells, and metastatic tumor cells from patients with prostate cancer Cancer Research. 75: 4880-4880. DOI: 10.1158/1538-7445.Am2015-4880 |
0.362 |
|
| 2015 |
Patel J, Bhargava V, He M, Foulk B, Smirnov DA, Twardowski P, Kortylewski M, Pal SK, Jones JO. Abstract 375: Phenotypic and molecular characterization of circulating tumor cells (CTCs) in patients with castration resistant prostate cancer (CRPC) undergoing treatment with abiraterone acetate or enzalutamide Cancer Research. 75: 375-375. DOI: 10.1158/1538-7445.Am2015-375 |
0.418 |
|
| 2015 |
Tew BY, Hong T, Pal SK, Kalkum M, Jones J. Abstract 1919: Warfarin-dependent gamma-carboxylation regulates androgen receptor activity Cancer Research. 75: 1919-1919. DOI: 10.1158/1538-7445.Am2015-1919 |
0.458 |
|
| 2015 |
Vuong W, Tew B, Little G, Frenkel B, Jones J. Small-Molecule Inhibition of the Androgen Receptor (AR)-RUNX2 Interaction in Prostate Cancer (PC) The Faseb Journal. 29. DOI: 10.1096/Fasebj.29.1_Supplement.945.10 |
0.442 |
|
| 2015 |
Moreira DF, Zhang Q, Hossain DM, Nechaev S, Li H, Kowolik CM, D'Apuzzo M, Forman S, Jones J, Pal SK, Kortylewski M. 698. Eliminating TLR9+ Prostate Cancer Stem Cells In Vivo Using NF-kB/RELA- or STAT3-Targeting CpG-siRNA Conjugates Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34307-6 |
0.463 |
|
| 2015 |
Hossain DMS, Moreira D, Jones J, Pal SK, Kortylewski M. 216. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33821-7 |
0.466 |
|
| 2014 |
Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. Prostate Cancer and Prostatic Diseases. 17: 292-9. PMID 25047002 DOI: 10.1038/Pcan.2014.27 |
0.44 |
|
| 2014 |
Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Research. 74: 2857-68. PMID 24648349 DOI: 10.1158/0008-5472.Can-13-2003 |
0.473 |
|
| 2014 |
Lim M, Otto-Duessel M, He M, Su L, Nguyen D, Chin E, Alliston T, Jones JO. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium. Acs Chemical Biology. 9: 692-702. PMID 24354286 DOI: 10.1021/Cb400759D |
0.433 |
|
| 2014 |
Pal SK, Ruel N, Vogelzang N, Chang M, Wilson TG, Jones JO, Yuh B. Preoperative androgen deprivation therapy for localized prostate cancer: delayed biochemical recurrence in high-risk disease. Clinical Genitourinary Cancer. 12: 149-54. PMID 24342128 DOI: 10.1016/J.Clgc.2013.11.009 |
0.418 |
|
| 2014 |
Pal SK, Tong T, He M, Wu H, Liu X, Nelson RA, Wu X, Signoretti S, Choueiri TK, Jones J. Deep sequencing of sarcomatoid renal cell carcinoma (sRCC) and identification of aurora kinases and mTOR as potential therapeutic targets. Journal of Clinical Oncology. 32: 411-411. DOI: 10.1200/Jco.2014.32.4_Suppl.411 |
0.325 |
|
| 2014 |
Pal SK, Hossain DMS, Zhang Q, Gao C, Jones JO, Frankel PH, Figlin RA, Kortylewski M. Abstract CT334: Pazopanib as third-line therapy for metastatic renal cell carcinoma: Clinical efficacy and temporal analysis of cytokine profile Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct334 |
0.335 |
|
| 2013 |
Tong T, He M, Wu H, Liu X, Carmichael C, Lau C, Nelson RA, Figlin RA, Jones J. Elevated pS6K levels in the sarcomatoid component of tumors derived from patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 475. PMID 28136841 DOI: 10.1200/Jco.2013.31.6_Suppl.475 |
0.306 |
|
| 2013 |
Zhou Y, Otto-Duessel M, He M, Markel S, Synold T, Jones JO. Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue. Journal of Molecular Endocrinology. 51: 143-53. PMID 23709748 DOI: 10.1530/Jme-13-0060 |
0.401 |
|
| 2013 |
Otto-Duessel M, He M, Adamson TW, Jones JO. Enhanced evaluation of selective androgen receptor modulators in vivo Andrology. 1: 29-36. PMID 23258627 DOI: 10.1111/J.2047-2927.2012.00006.X |
0.404 |
|
| 2013 |
Pal S, Lau C, He M, Linehan J, Wilson T, Twardowski P, Nazmy M, Kawachi M, Torres A, Carmichael C, Yen Y, Kortylewski M, Jones J. 2138 Circulating Tumor Cells (Ctcs) Are Detectable In Patients With High-Risk, Localized Prostate Cancer Through Use Of The Cellsearch Platform The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2047 |
0.415 |
|
| 2012 |
Otto-Duessel M, He M, Jones JO. Tissue-selective regulation of androgen-responsive genes. Endocrine Research. 37: 203-15. PMID 22591338 DOI: 10.3109/07435800.2012.668254 |
0.329 |
|
| 2012 |
Pal SK, Lau C, He M, Twardowski P, Wilson TG, Kawachi MH, Torres A, Carmichael C, Yen Y, Kortylewski M, Jones J. Detecting circulating tumor cells (CTCs) in patients with high-risk, localized prostate cancer using the CellSearch platform. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15178 |
0.4 |
|
| 2012 |
Hsu J, Pal SK, Twardowski P, Carmichael C, Saikia J, Liu X, Wilson TG, Figlin RA, Jones J. Clinical outcome and molecular characterization of patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15084 |
0.301 |
|
| 2011 |
Khalil MI, Arvin A, Jones J, Ruyechan WT. A sequence within the varicella-zoster virus (VZV) OriS is a negative regulator of DNA replication and is bound by a protein complex containing the VZV ORF29 protein. Journal of Virology. 85: 12188-200. PMID 21937644 DOI: 10.1128/Jvi.05501-11 |
0.475 |
|
| 2009 |
Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, Hann B, Diamond MI. Non-competitive androgen receptor inhibition in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 106: 7233-8. PMID 19363158 DOI: 10.1073/Pnas.0807282106 |
0.433 |
|
| 2009 |
Jones JO, An WF, Diamond MI. AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. Acs Chemical Biology. 4: 199-208. PMID 19236099 DOI: 10.1021/Cb900024Z |
0.329 |
|
| 2008 |
Jones JO, Diamond MI. A cellular conformation-based screen for androgen receptor inhibitors. Acs Chemical Biology. 3: 412-8. PMID 18582038 DOI: 10.1021/Cb800054W |
0.372 |
|
| 2007 |
Cvoro A, Paruthiyil S, Jones JO, Tzagarakis-Foster C, Clegg NJ, Tatomer D, Medina RT, Tagliaferri M, Schaufele F, Scanlan TS, Diamond MI, Cohen I, Leitman DC. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology. 148: 538-47. PMID 17095596 DOI: 10.1210/En.2006-0803 |
0.329 |
|
| 2007 |
Harzstark AL, Ryan C, Diamond M, Jones J, Zavodovskaya M, Maddux B, Claros C, Goldfine I, Small EJ. A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA Journal of Clinical Oncology. 25: 15500-15500. DOI: 10.1200/Jco.2007.25.18_Suppl.15500 |
0.402 |
|
| 2006 |
Jones JO, Arvin AM. Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. Journal of Virology. 80: 5113-24. PMID 16698992 DOI: 10.1128/Jvi.01956-05 |
0.483 |
|
| 2006 |
Jones JO, Sommer M, Stamatis S, Arvin AM. Mutational analysis of the varicella-zoster virus ORF62/63 intergenic region. Journal of Virology. 80: 3116-21. PMID 16501125 DOI: 10.1128/Jvi.80.6.3116-3121.2006 |
0.471 |
|
| 2005 |
Jones JO, Arvin AM. Viral and cellular gene transcription in fibroblasts infected with small plaque mutants of varicella-zoster virus. Antiviral Research. 68: 56-65. PMID 16118026 DOI: 10.1016/J.Antiviral.2005.06.011 |
0.493 |
|
| 2003 |
Jones JO, Arvin AM. Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. Journal of Virology. 77: 1268-80. PMID 12502844 DOI: 10.1128/Jvi.77.2.1268-1280.2003 |
0.506 |
|
| Show low-probability matches. |